US-Europe BT disharmony chills products to market
Ronit Langer & Shruti Sharma, 11-20-2020, Carnegie Endowment for International Peace (Technology and International Affairs Fellow & Technology and Society Sr. Research Analyst), https://carnegieendowment.org/2020/11/20/blessing-and-curse-of-biotechnology-primer-on-biosafety-and-biosecurity-pub-83252, "The Blessing and Curse of Biotechnology: A Primer on Biosafety and Biosecurity," (ermo/sms, Acc:6-8-2022)
Real-world applications are integral to the successful development and use of biotechnology. In the pharmaceutical industry, for instance, streamlining the process of getting new treatments to market is called translational medicine. Standard procedures for proving that a new treatment is safe and effective include animal models and clinical trials.
For agricultural biotechnology, this process is less defined. Many countries, particularly members of the European Union, ban the growing of genetically modified organisms (GMOs) or crops. In countries where GMOs are allowed, regulations are often shifting due to public pressure from anti-GMO organizations and differing definitions of the term genetically modified. Once a GMO product enters the market, companies must navigate the complicated information landscape surrounding GMOs and provide evidence to consumers that their product is safe.
For environmental biotechnology, the processes of getting products to market has not been established yet. The applications of environmental biotechnology often fall outside of existing regulatory frameworks. Applications often span many national borders, such as gene drives being considered to help eradicate malaria-causing mosquitoes in sub-Saharan Africa. In some cases, these applications fall outside of national borders altogether, such as in the case of bacteria designed to break down oil from oil spills.